So this trial is also with the actinium 225-based isotope radioligand therapy agent. Instead of PSMA 617, they use another ligand specific to PSMA as well, J591. It’s an antibody, so it has a different biodistribution profile, of course, much bigger, so it circulates very long in the blood circulation, but with potentially higher uptake. Here, they tested a different dosing schedule...
So this trial is also with the actinium 225-based isotope radioligand therapy agent. Instead of PSMA 617, they use another ligand specific to PSMA as well, J591. It’s an antibody, so it has a different biodistribution profile, of course, much bigger, so it circulates very long in the blood circulation, but with potentially higher uptake. Here, they tested a different dosing schedule. It’s only two doses back-to-back with two weeks’ time interval, and that’s it. It’s not six cycles in the other common PSMA radio ligand therapy approaches. They also did a dose escalation phase. Initially, it was weight-based. It was 45 kilobecquerel per kilo and 55 kilobecquerel per kilo. And they tried in several patients in the dose escalation. I think they will move to a fixed injected activity instead of the weight-based dose injected activity. They analyze based on the weight dose the different injected activity level because they have a variation and they will choose finally the nine megabecquerel dose for the next phase three trial.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
